Global CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells, Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation CAR-T Cells, Third Generation CAR-T Cells, Fourth Generation CAR-T Cells), Targeted Antigens (Antigens on Solid Tumors, Antigens on Hematologic Malignancies, Others), Brand (Yescarta, Kymriah, Tecartus, Others), Therapeutic Application (Hematological Malignancies, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Others), End-User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospitals Pharmacy, Others) - Industry Trends and Forecast to 2030.
CAR-T Cell Therapy Treatment Market Analysis and Size
CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein.
Data Bridge Market Research analyses that the CAR-T cell therapy treatment market which is expected to undergo a CAGR of 32.3% during the forecast period of 2023 to 2030. “Autologous CAR-T Cells” dominates the product segment of the CAR-T cell therapy treatment market owing to the rising pharmaceutical industries. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
CAR-T Cell Therapy Treatment Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2021) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Product (Autologous CAR-T Cells, Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation CAR-T Cells, Third Generation CAR-T Cells, Fourth Generation CAR-T Cells), Targeted Antigens (Antigens on Solid Tumors, Antigens on Hematologic Malignancies, Others), Brand (Yescarta, Kymriah, Tecartus, Others), Therapeutic Application (Hematological Malignancies, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Others), End-User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospitals Pharmacy, Others) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Kuwait, Egypt and Rest of Middle East and Africa. |
|
Market Players Covered |
|
|
Market Opportunities |
|
Market Definition
Chimeric antigen receptor T-cell treatment, often known as CAR T-cell therapy, is a revolutionary immunotherapy strategy used to treat specific cancers. In order to express a chimeric antigen receptor (CAR) on their surface, it entails genetically altering a patient's own T cells, an immune cell subtype. Targeting particular antigens present on cancer cells is the goal of this modified receptor.
CAR-T Cell Therapy Treatment Market Dynamics
Drivers
- Growing Prevalence of Targeted Therapies
CAR T-cell therapies have been made possible by the development of precision medicine and targeted therapeutics. These therapies minimise damage to healthy tissue and cut down on adverse effects by targeting particular antigens on cancer cells
- Rising Technological Advancements
Gene editing tools, such as CRISPR/Cas9, have improved the design and personalization of CAR T-cell treatments, boosting their safety and efficacy. These ongoing improvements in cell engineering techniques
- Increasing Funding by Public Private Authorities
Both public and private sources have made considerable investments in the CAR T-cell therapy business. The development of novel cures and technologies has been expedited by the financial support for research and development
Opportunities
- Growing Demand of Personalized Medicine
The creation of personalised CAR T-cell therapies that are catered to specific patients is made possible by advances in genomic and biomarker research. This strategy may result in treatments that are more specialised, efficient, and have fewer adverse effects
- Emerging Market with Expansion
There are no geographical restrictions on CAR T-cell treatments. If businesses can manage legislative variations and market specific obstacles, opening up the market to more nations and regions offers significant growth prospects
Restrains/ Challenges
- Strict Regulations
Living cells are frequently manipulated during cell treatments, which provides special regulatory difficulties. Due to the importance of ensuring the efficacy and safety of these medicines, strict regulatory procedures must be followed. Overcoming these regulatory barriers may cause market entry to be delayed and development expenses to rise
- High Development Costs
The process of creating cell treatments is time consuming and expensive. The expenditures can be unreasonably costly for everything from research and clinical trials to manufacturing and regulatory approvals. As a result, there may be fewer businesses ready to invest in the development of cell therapies, which could raise the price of patient care
- Long Term Safety and Efficacy
Due to the relatively recent development of cell therapies, there are frequently few long-term safety and efficacy data available. Building confidence among healthcare professionals, payers, and patients requires regular monitoring and evaluation of patients undergoing cell treatments
This CAR-T cell therapy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the CAR-T cell therapy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Global CAR-T Cell Therapy Treatment Market Scope
The CAR-T cell therapy treatment market is segmented on the basis of the product, structure, targeted antigens, brand, therapeutic application, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Product
- Autologous CAR-T Cells
- Allogeneic CAR-T Cells
Structure
- First Generation CAR-T Cells
- Second Generation CAR-T Cells
- Third Generation CAR-T Cells
- Fourth Generation CAR-T Cells
Targeted Antigens
- Antigens on Solid Tumors
- Antigens on Hematologic Malignancies
- Others
Brand
- Yescarta
- Kymriah
- Tecartus
- Others
Therapeutic Application
- Hematological Malignancies
- Pancreatic Cancer
- Breast Cancer
- Lung Cancer
- Gastric Cancer
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Acute Lymphoblastic Leukemia
- Others
End-User
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospitals Pharmacy
- Others
CAR-T Cell Therapy Treatment Market Regional Analysis/Insights
Global CAR-T cell therapy treatment market is analyzed and market size information is provided on basis of product, structure, targeted antigens, brand, therapeutic application, end-user and distribution channel as referenced above.
The countries covered in the global CAR-T cell therapy treatment market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Kuwait, Egypt and rest of Middle East and Africa
The North America is dominating in the global CAR-T cell therapy treatment market and is expected to grow with the highest growth rate in the forecast period of 2023 to 2030 because of increasing healthcare expenditure and well established healthcare infrastructure for the autologous CAR-T cells segment. Asia-Pacific is leading the growth of the global CAR-T cell therapy treatment market and autologous CAR-T cells segment is dominating in the country due to increase in research regarding CAR-T cell therapy treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
CAR-T cell therapy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and CAR-T Cell Therapy Treatment Market Share Analysis
The CAR-T cell therapy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to global API intermediates market.
Some of the major players operating in the CAR-T cell therapy treatment market are:
- Autolus (U.K.)
- Atara Biotherapeutics, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Bellicum Phamaceuticals, Inc. (U.S.)
- bluebird bio, Inc. (U.S.)
- Adaptimmune Therapeutics plc (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Xyphos (a subsidiary of Astellas Pharma Inc.) (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- BioAtla Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Novartis AG (Switzerland)
- Kite Pharma (a subsidiary of Gilead Sciences, Inc.) (U.S.)
- Aurora Biopharma (U.S.)
- Tmunity Therapeutics (U.S.)
- Cartherics pty. Ltd (Australia)
- CARINA BIOTECH (Australia)
- Ziopharm Oncology, Inc. (U.S.)
- Cellectis SA (France)
- Mustang Bio (U.S.)
- Sorrento Therapeutics, Inc. (U.S.)
- Cartesian Therapeutics, Inc. (U.S.)
- TC BioPharm Limited (U.K.)
- Celyad Oncology SA (Belgium)
- Tessa Therapeutics Ltd. (Singapore)
SKU-
